Patients with heart failure with reduced ejection fraction are treated with a beta blocker, a converting enzyme inhibitor or a neprilysin inhibitor, a mineralocorticoid receptor antagonist, and sodium–glucose cotransporter-2 inhibitors. Here, MME is linked to heart failure.